Skip to content

Main Navigation

About us
Research and development
Partnering
Investors
Newsroom
Careers

test

Search

Recent Posts

ASCO 2025: Introduction of Neoantigen-Specific Immune Responses by VB10.NEO in Combination with Atezolizumab in Heavily Pretreated Patients with Advanced Solid Tumors: Final Analysis of the Phase 1b VB-N-02 Trial
ASCO 2025: Integrative analysis of VB10.16 and atezolizumab in advanced HPV16-positive cervical cancer: Linking biomarker insights to clinical outcomes
Nykode Therapeutics reports Q1 2025 Financial Results
Nykode Therapeutics – invitation to Q1 2025 financial results presentation
Nykode Therapeutics Highlights New Data in Two Poster Presentations at the 2025 ASCO Annual Meeting

Recent Comments

Vaccibody Granted Platform Patent in the US (16.02.15) | Sarsiaseed on Vaccibody Granted Platform Patent in the US
Vaccibody får viktig patent godkjent i USA (16.02.15) | Sarsiaseed on Vaccibody Granted Platform Patent in the US

Contact

Headquarter, Norway
Nykode Therapeutics ASA
Oslo Science Park, Gaustadalléen 21
0349 Oslo
Norway
Phone +47 22 95 81 93

Office, Denmark
Gammel Lundtoftevej 1E, 3. Sal.
2800 Lyngby
Denmark

Privacy statement
Cookie policy
Disclaimer